The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Investigational New Drugs · 2024
DOI: 10.1007/s10637-024-01436-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Bei Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trials Unit, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Zhongshan Road 321#, Gulou Dist…. Hauptthemen laut MEDLINE: Cross-Over Studies, ErbB Receptors, Food-Drug Interactions, Healthy Volunteers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Funding for Clinical Trials from Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Natural Science Foundation of Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
Sutetinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and showed favorable efficacy and safety in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring nondrug-resistant rare EGFR mutations. To evaluate the potential food effect, eighteen healthy Chinese subjects were enrolled in a single-centre, randomized, open-label, two-sequence, two-period crossover study. Sutetinib was administered as a single oral 100 mg under fasting or fed conditions, and pharmacokinetic sampling was performed following each dose and analysed by a validated liquid chromatography/mass spectrometry method. Safety and tolerability were also evaluated. Food intake slightly decreased maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time 0 to infinity (AUC0 - inf) of sutetinib (geometric least-squares mean [GLSM] ratio, 80.94% and 86.11%; 90% confidence interval [CI], 68.43-95.72 and 75.88-97.73) and its active metabolite sutetinib N-Oxide (GLSM ratio, 75.58% and 84.00%; 90% CI, 65.69-86.95 and 75.42-93.56), respectively. In addition, the time to maximum plasma concentration (Tmax) of both sutetinib and its metabolite has been prolonged by 2 h under fed conditions. A total of 31 adverse events (AEs) occurred during the study, with no serious adverse events (SAE) reported, and no obvious difference was observed between the fasting and fed groups. Our results demonstrated that a high-fat and high-calorie diet caused a significant delay in drug absorption and a marginal reduction in drug exposure. Sutetinib was generally well tolerated in healthy Chinese subjects. (This trial was registered at http://www.chinadrugtrials.org.cn . The registration No. is CTR20201933, and the date of registration is 2020-10-16).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trials Unit, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Zhongshan Road 321#, Gulou District, 210008, Nanjing, China.
- Clinical Pharmacology Department, Suzhong pharmaceutical group co., LTD, 22550, Taizhou, China.
- Clinical Pharmacology Department, Suzhong pharmaceutical group co., LTD, 22550, Taizhou, China. caosm@suzhongyy.com.
- Phase I Clinical Trials Unit, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Zhongshan Road 321#, Gulou District, 210008, Nanjing, China. juanli2003@163.com.
Förderung
- Funding for Clinical Trials from Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
- Natural Science Foundation of Nanjing University of Chinese Medicine
Zitieren
APA
Cao, B., Ma, T., Zhang, Y., Huang, L., Lin, H., Jiang, H., Zhao, Y., Geng, Y., Yang, Y., Cao, S., & Li, J. (2024). The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01436-0
Vancouver
Cao B, Ma T, Zhang Y, Huang L, Lin H, Jiang H, et al. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01436-0
BibTeX
@article{Cao2024,
author = {Cao, Bei and Ma, Tingting and Zhang, Yuqiang and Huang, Lei and Lin, Hui and Jiang, Huanhuan and Zhao, Yu and Geng, Yan and Yang, Yuanxun and Cao, Sumin and Li, Juan},
title = {The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects},
journal = {Investigational New Drugs},
year = {2024},
doi = {10.1007/s10637-024-01436-0}
}
EUVIMED